Short Interest in Senti Biosciences, Inc. (NASDAQ:SNTI) Drops By 33.9%

Senti Biosciences, Inc. (NASDAQ:SNTI) was the recipient of a large decline in short interest in the month of February. As of February 15th, there was short interest totalling 68,600 shares, a decline of 33.9% from the January 31st total of 103,800 shares. Currently, 2.2% of the company’s shares are short sold. Based on an average daily trading volume, of 2,240,000 shares, the short-interest ratio is currently 0.0 days.

Senti Biosciences Price Performance

Shares of NASDAQ:SNTI opened at $3.01 on Friday. The firm has a market capitalization of $14.50 million, a PE ratio of -0.19 and a beta of 2.46. The firm’s 50-day moving average is $4.11 and its two-hundred day moving average is $3.36. Senti Biosciences has a 1 year low of $1.52 and a 1 year high of $16.94.

Institutional Trading of Senti Biosciences

A hedge fund recently bought a new stake in Senti Biosciences stock. Virtu Financial LLC purchased a new position in shares of Senti Biosciences, Inc. (NASDAQ:SNTI) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,356 shares of the company’s stock, valued at approximately $47,000. Virtu Financial LLC owned 0.28% of Senti Biosciences at the end of the most recent reporting period. 25.73% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Chardan Capital restated a “buy” rating and issued a $10.00 price objective on shares of Senti Biosciences in a report on Monday, December 2nd.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.